All rights reserved. No reuse allowed without permission.

# **Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients**

5 Tesa M. Severson<sup>1,2,3,\*</sup>, Yanyun Zhu<sup>1,2,\*</sup>, Stefan Prekovic<sup>1,2,\*</sup>, Karianne Schuurman<sup>1</sup>, Holly M. 6 Nguyen<sup>4</sup>, Lisha G. Brown<sup>4</sup>, Sini Hakkola<sup>5</sup>, Yongsoo Kim<sup>1,6</sup>, Jeroen Kneppers<sup>1,2</sup>, Simon 7 Linder<sup>1,2</sup>, Suzan Stelloo<sup>1,2,7</sup>, Cor Lieftink<sup>3</sup>, Michiel van der Heijden<sup>3,8</sup>, Matti Nykter<sup>5</sup>, Vincent 8 van der Noort<sup>9</sup>, Joyce Sanders<sup>10</sup>, Ben Morris<sup>3</sup>, Guido Jenster<sup>11</sup>, Geert JLH van Leenders<sup>12</sup>, Mark Pomerantz<sup>13</sup>, Matthew L. Freedman<sup>13,14</sup>, Roderick L. Beijersbergen<sup>3</sup>, Alfonso 10 Urbanucci<sup>5,15</sup>, Lodewyk Wessels<sup>2,3,16</sup>, Eva Corey<sup>4</sup>, Wilbert Zwart<sup>1,2,17#</sup>, Andries M. 11 Bergman<sup>1,8#</sup>

- 
- **1** Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- **2** Oncode Institute, Utrecht, the Netherlands
- **3** Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the
- Netherlands
- **4** Department of Urology, University of Washington, Seattle, WA, USA
- **5** Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
- **6** present working address: Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- **7** present working address: Department of Molecular Biology, Faculty of Science, Radboud
- Institute for Molecular Life Sciences, Oncode Institute, Radboud University, Nijmegen, 6525
- GA Nijmegen, the Netherlands.
- **8** Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- **9** Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- **10** Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- **11** Department of Urology, Erasmus MC, Rotterdam, the Netherlands
- **12** Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
- **13** Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- **14** The Eli and Edythe L. Broad Institute, Cambridge, MA, USA
- **15** Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- **16** Department of EEMCS, Delft University of Technology, Delft, the Netherlands.
- **17** Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department
- of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the
- Netherlands.
- 
- \*shared first authors
- 43 # corresponding authors: w.zwart@nki.nl, a.bergman@nki.nl
- 
- 
- **Keywords:** mCRPC, enzalutamide, epigenetics, androgen receptor, H3K27ac, HDAC inhibitors, biomarkers, hormone intervention **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
	-

## **Abstract**

 Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase II clinical trial, we epigenetically profiled enhancer/promoter activities with H3K27ac chromatin immunoprecipitation followed by sequencing, before and after AR-targeted therapy. We identified a distinct subset of H3K27ac-differentially marked regions that associated with treatment responsiveness. These data were successfully validated in mCRPC patient- derived xenograft models (PDX). *In silico* analyses revealed HDAC3 as a critical factor that can drive resistance to hormonal interventions, which we validated *in vitro*. Using cell lines and mCRPC PDX tumors *in vitro*, we identified drug-drug synergy between enzalutamide and the pan-HDAC inhibitor vorinostat, providing therapeutic proof-of-concept. These findings demonstrate rationale for new therapeutic strategies using a combination of AR and HDAC inhibitors to improve patient outcome in advanced stages of mCRPC.

- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

### **Background**

 Prostate cancer is the most prevalent cancer type in men, with globally over 1.4 million new diagnoses and 375,000 patients who succumb to the disease each year<sup>1</sup>. Although most patients with high-risk localized disease are effectively treated with either prostatectomy or 78 radiotherapy<sup>2</sup>, eventually 25% of patients will develop metastases for which there is currently no cure<sup>3-5</sup>. Treatment of choice for metastatic prostate cancer patients is androgen deprivation therapy (ADT) which reduces serum testosterone to castration levels, to which virtually all patients initially respond. However, metastatic disease progression despite ongoing ADT, termed metastatic castration-resistant prostate cancer (mCRPC), is 83 inevitable<sup>6</sup>.

 Androgen Receptor (AR) is a hormone-dependent transcription factor and the master regulator of prostate cancer development and progression. Upon androgen stimulation, AR alters its conformation, translocates into the nucleus<sup>7</sup> and associates to the chromatin at distal regulatory elements throughout the genome, hereafter referred to as its 'cistrome'. AR 89 chromatin binding is facilitated by pioneer factors, such as FOXA1<sup>8</sup>, and operates under tight 90 epigenetic control<sup>8,9</sup>. The majority of active AR sites are hallmarked by acetylation of lysine 91 residue 27 on histone 3 (H3K27ac), a marker of active enhancers and promoters<sup>10,11</sup>. Upon formation of an active transcription complex, AR drives the expression of its target genes to control tumor cell growth. Following progression on ADT, further suppression of the AR signaling axis by new generation AR inhibitors, such as enzalutamide, is an effective 95 treatment for mCRPC patients $12,13$ .

 Enzalutamide (ENZA) is a well-established therapy for the treatment of mCRPC. It significantly decreases the risk of radiographic progression and death among mCRPC 99 patients in both the pre- and post-chemotherapy settings<sup>12,13</sup>. ENZA blocks AR signaling at multiple levels, including diminished AR chromatin binding, and prevention of coregulator 101 recruitment<sup>14</sup>. However, intrinsic resistance to ENZA is observed in up to 46% of mCRPC 102 patients and duration of response varies greatly between patients<sup>12,13</sup>. Consequently, biomarkers for response prediction to AR-targeted therapeutics, including ENZA, are urgently needed to identify those patients who may benefit from alternative treatment strategies. Moreover, combination treatments to overcome or postpone resistance to AR-targeted 106 therapies, are urgently needed in the clinic.

 Several studies have previously compared AR chromatin binding profiles in different disease 109 stages and illustrated plasticity of AR cistromes in tumor development<sup>15,16</sup> and disease 110 progression<sup>17,18</sup>, being predictive for outcome<sup>17</sup> and associated with treatment response in cell lines<sup>9</sup>. Despite our expanding knowledge of AR epigenetic alterations in prostate cancer patients and cell line models, there is limited knowledge on FOXA1 cistromics and H3K27ac profiles, in relation to drug resistance in mCRPC patients.

 To identify the potential epigenetic alterations that drive ENZA response in mCRPC patients, metastasis-targeted biopsies were collected pre- and post- AR-targeting treatment, while response to treatment was monitored. Chromatin immunoprecipitation followed by massive parallel sequencing (ChIP-seq) was performed on all collected clinical specimens, charting the cistromes of H3K27ac, AR and FOXA1.

 Comparative data analyses revealed a specific subset of 657 H3K27ac sites significantly enriched in metastatic lesions from mCRPC patients who did not respond to AR-targeted treatment. These sites were associated with response to castration in mCRPC PDX models, and regulate genes selectively expressed in ENZA-resistant cell line models, illustrating their potential to predict treatment response. Finally, we identified and functionally assessed factors that selectively bind to these 657 resistance-associated H3K27ac sites in cell line models, revealing novel therapeutic candidates and effective drug-drug combinations for treatment-resistant mCRPC patients.

### **Methods**

## *Study design and participants*

 We conducted a single-arm, open-label, phase 2 study, in patients with mCRPC at the Netherlands Cancer Institute. Male patients over 18 years of age, with histologically confirmed adenocarcinoma of the prostate, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, a serum testosterone level <50 ng/dl, scheduled for ENZA treatment and not previously treated with ENZA, with progressive disease, defined as a PSA rise 137 (PCWG3 criteria<sup>19</sup>) and/or radiographic progression (RECIST 1.1 criteria<sup>20</sup>) and metastatic lesions of which a histological biopsy could safely be obtained, were included in the trial. This single center cohort study was conducted as a sub-investigation of the CPCT-02 biopsy protocol (NCT01855477), which aims to analyze the individual metastatic cancer genome in patients, to develop future personal predictors for response to systemic treatment. Trial procedures, treatment details, patient on-trial monitoring, definition of endpoints, sample size calculations and statistical analysis, are included in the supplementary trial data (Supplementary Data). This study was approved by the local medical ethics committee of the 145 Netherlands Cancer Institute and was activated on January 24<sup>th</sup>, 2012. The protocol complied

 with the ethical principles of the Declaration of Helsinki. Patients provided signed informed consent for translational studies and recording and analysis of baseline characteristics and clinical outcomes of ENZA treatment.

*Tissue processing and chromatin immunoprecipitation analyses*

 Biopsies were taken from a lymph-node metastasis or visceral metastasis selected by CT 152 scan, while sites for a biopsy from a bone metastasis were selected by  $68Ga-PSMA PET$  scanning. Fresh-frozen metastatic biopsy samples from 64 CRPC patients was collected. The tumor percentage of these samples was scored on hematoxylin and eosin (H&E) stained slides by a dedicated pathologist. After tumor cell content was confirmed, chromatin immunoprecipitations were performed for AR, FOXA1 and H3K27ac at qualified samples as 157 previously described<sup>21-23</sup>. In brief, lymph-node and visceral samples were cryo-sectioned into 158 slices of  $30\mu$ m, while bone samples were cryo-sectioned to slices of  $10\mu$ m, and crosslinked 159 using DSG (20593; Thermo Fisher Scientific) for 25 min. For each sample, 5µg of antibody and 50µl of either Protein A or Protein G magnetic beads (10008D or 10009D; Thermo Fisher Scientific) were used. Inputs for individual patients were generated as controls. Antibodies used were: AR (Millipore, 06-680), FOXA1 (Abcam, ab5089) and H3K27ac (Active motif, 39133). Libraries were prepared and sequenced using the Illumina HiSeq2500 (65 bp, single end).

*ChIP-seq data analysis*

 Raw sequence data were aligned to hg19 using BWA v0.5.20. Aligned reads were filtered for 168 mapping quality (MQ) > 20 using samtools v1.8<sup>24</sup>. Duplicate reads were marked using Picard MarkDupes function v2.18 (http://broadinstitute.github.io/picard/). Peaks were called using 170 macs2  $(v2.1.1)^{25}$  with the fragment size determined using Phantompeakqualtools<sup>26</sup> against

 corresponding input DNA for all samples. Phantompeakqualtools was used to identify the 172 Relative Strand Cross-correlation (RSC)<sup>26</sup> and deepTools (v2.0)<sup>27</sup> to determine the fraction 173 of reads in peaks (FRiP) and readcounts. Samples with RSC > 0.7, FRiP  $\geq$  1.0 and ≥ 8,000 peaks were kept for further analysis (Supplementary Table 3). Snapshots of raw signal were 175 generated using pyGenomeTracks (v3.6) with bigwig files<sup>28</sup>. Bigwig files were generated from aligned bam files using deepTools v2.0 bamCoverage function. To correlate read count data in 50kb bins across the genome for all samples and PDX samples, deepTools computeMatrix function was used on bigwigs followed by plotCorrelation. Visualization of raw reads was carried out with bigwigs using deepTools (v2.0) computeMatrix, plotHeatmap and plotProfile functions. For visualizing profiles of binding data between groups (non- responders/responders) at specific regions, aligned files from the samples within groups were merged and subsequently downsampled to equivalent readcounts (~20 million reads) using samtools and visualized using deepTools plotProfile. Principal component analysis was carried out using plotPCA function with the reads counted in peaks (dba.count function) from DiffBind package v2.4.8 in R v3.4.4. Supervised differential analyses using dba.analyze and resulting heatmap and volcano plot were generated using the DiffBind package (v2.4.8 in R v3.4.4) with the reads counted in peaks using the dba.count function using default DESeq2 method. Volcano plot hexbin density tiles were plotted with R package hexbin (v1.28.1). 189 Genomic features were assigned to differential peaksets using ChIPSeeker (v1.26.2)<sup>29</sup> in R (v4.0.3).

 To compare H3K27ac signal across various samples in our non-responder H3K27ac regions 193 of interest, we first downloaded public PDX mCRPC H3K27ac ChIP-seq data<sup>18</sup> (GSE130408) and additional H3K27ac data from primary prostate cancer patient tumors (e.g. Gleason 7,9, 195 cases, controls (GSE120738))<sup>30</sup> and aligned as above. In addition, we examined H3K27ac

 data in the same manner from in-house generated datasets from treatment naïve metastatic samples, non-responder metastatic samples (this study), and publicly available healthy and 198 primary tumor tissue (GSE130408)<sup>18</sup>. Visualizations of these data were generated with deepTools v2.0 computeMatrix followed by plotHeatmap of individual files and plotProfile as described above for binding data between groups.

201

202 For gene set enrichment, genes associated with H3K27ac non-responder sites (within 50kb 203 of a transcription start site (TSS)) were identified in R (v4.0.3) using the ChIPSeeker package  $(204)$  (v1.26.2)<sup>29</sup>. Enrichment tests for gene sets were performed in R (v4.1.2) using the 205 GeneOverlap package (v1.30.0) and visualized in ggplot (v3.4.0). The average gene 206 expression of these genes was calculated and plotted in public scRNA-seq from parental 207 LNCaP cells and cells exposed to ENZA until resistance arose (RES-B $31,32$ ) using the Seurat 208 package  $(v4.3.0)^{33}$  in R  $(v4.1.2)$ .

209

210 Readcounts and fraction of reads in peaks (FrIP) were visualized using the gaplot2 v2.3.3.0 211 with Wilcoxon tests performed with ggpubr package v0.3.0 in R v3.5.0. To determine 212 significant enrichment of our intervals with publicly available ChIP-seq data we queried our 213 intervals against the CistromeDB transcription factor dataset<sup>34</sup> using the GIGGLE search 214  $\cdot$  function<sup>35</sup>. Prostate and prostate cancer experiments (Supplemental Table 5) were selected 215 specifically for analysis. A scatterplot of the mean Enrichment score (combo\_score) for each 216 factor was generated using gaplot  $v2.3.3.0$  in R  $v3.5.0$  (Supplemental Table 5).

217

## 218 *Patient-derived xenograft studies*

219 All animal experiments were performed after University of Washington IACUC approval 220 following ARRIVE and NIH guidelines. Subcutaneous tumors were implanted in intact C.B.

221 17 SCID male mice (Charles River) and when tumors reached 100 mm<sup>3</sup> animals were 222 randomized to control and castrated groups. Tumor growth and body weights were monitored 223 twice a week. Animals were sacrificed at the end of the study or when animals became 224 compromised. Responses to castration were also fully described previously<sup>36</sup>. The doubling 225 time was estimated using exponential (Malthusian) growth model. If only one value was 226 available, doubling time was not computed. For samples with a negative doubling time, the 227 value was re-normalized to the mean value of the corresponding control model yielding a 228 positive value. Significant differences between classes determined by one-way ANOVA 229 followed by post-hoc Tukey HSD test. Visualization was carried out in R using ggplot (v3.3.6)

230

## 231 *Cell lines and culture conditions*

232 Castration-resistant prostate cancer models (LNCaP-Abl and LNCaP-16 $D^{37}$ ) were kindly 233 provided by Helmut Klocker<sup>38</sup> and Amina Zoubeidi<sup>39</sup>. ENZA resistant LNCaP derivatives 234 LNCaP-Enz<sup>R</sup> were kindly provided by the Donald Vander Griend<sup>40</sup>. LNCaP-Abl cells were 235 cultured in RPMI-1640 medium containing 10% DCC (hormone deprived FBS), LNCaP-16D<sup>37</sup> 236 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, and LNCaP-EnzR 237 cells were cultured in RPMI-1640 medium containing 10% FBS and 10uM ENZA. All cell lines 238 were authenticated and tested for mycoplasma contamination.

239

# 240 *siRNA screen proliferation assay and analyses*

241 siRNAs were purchased from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA and 242 siPLK1 were applied as positive and negative controls. 5µl of 50nM siRNA pools were seeded 243 in individual wells of a 96 well-plate. Cells were reverse transfected with 5ul 1% Lipofectamine 244 RNAiMAX Reagent (Invitrogen, Eindhoven, Netherlands) in Optimem (Thermofisher, 245 Eindhoven, Netherlands) in 90ul culture medium. For LNCaP-Abl and LNCaP-16D, 10.000 246 cells were seeded per well, and 20.000 cells for  $LNCaP-Enc<sup>R</sup>$  cells. Optimal experimental setup was determined for each cell line and after 7 (LNCaP-16D), 9 (LNCaP-Abl) and 10 (LNCaP-Enz<sup>R</sup>) days, cell viability was determined using CellTiter-Blue and values were normalized over siControl. After incubating for 3 hours, viability was measured using a fluorescence reader (EnVision 2014).

 The primary pooled siRNA and validation deconvolution screen were analysed in the following way. Using the CellTiter-Blue measurements of the positive and negative controls, a z'factor was calculated per plate and plates with a z'factor < 0 were removed from the 255 dataset. The data was then normalized using Normalized percent inhibition<sup>41</sup>. After normalization, correlations between replicate plates were calculated and plates which did not 257 correlate well with the other replicate plates, were removed. Over the replicates a mean value was calculated. Per condition a normalized distribution for mean values of the negative controls was approximated based on mean and SD value, and used to calculate for each pooled siRNA a p-value, which was corrected for multiple testing using the Benjamini- Hochberg method. From the primary screen an initial selection was made of the siRNA pools that were a hit in at least two out of three cell lines, which produced a list of 11 hits. The 11 hits from the primary pooled screen were subsequently selected for a deconvolution validation screen, in which four individual siRNAs were tested separately. All 265 targets with two individual siRNAs with among replicates a mean  $\leq$  0.7 and FDR  $\leq$  0.1, where considered validated hits. All calculation were done in R.

 Expression levels per target gene in siRNA deconvolution experiments were assessed by means of qPCR analysis, using specific primer-pairs for ACTB (5'- CCTGGCACCCAGCACAAT-3', 5'-GGGCCGGACTCGTCATACT-3'), FOXA1 (FW 5'-

 GTGAAGATGGAAGGGCATGAA-3', REV 5'-CCTGAGTTCATGTTGCTGACC-3'), ASH2L (FW 5'-CTGACGTCTTGTATCACGTG-3', REV 5'-GCATCTTTGGGAGAACATTTG-3'), GATA2 (FW 5'-GACAAGGACGGCGTCAAGTA-3', REV 5'-GGTGCCCATAGTAGCTAGGC- 3') and HDAC3 (FW 5'-ACGGTGTCCTTCCACAAATACG-3', REV 5'- GGTGCTTGTAACTCTGGTCATC-3'). In brief, after siRNA transfection using the abovementioned protocol RNA was isolated using RNAGEM kit (MicroGEM), and quantified by Quant-iT™ RiboGreen™ RNA Assay Kit (Thermo Fisher Scientific), following quantification cDNA was synthesized using the SuperScript™ III Reverse Transcriptase system (Thermo Fisher Scientific, USA) with random hexamer primers according to the instructions provided by manufacturers. Quantitative PCR (qPCR) was performed using the SensiMix™ SYBR Kit (Bioline, UK) according to the manufacturer's instructions on a QuantStudio™ 6 Flex System (Thermo Fisher Scientific, USA). All data was firstly normalized over ACTB expression, and then over the siControl values. For all primer pairs, 2 biological replicates with 2 technical replicates each were analyzed.

#### *PDX in vitro studies*

 Subcutaneous tumors were harvested and dissociated using the Miltenyi gentleMACS system with a Human Tumor dissociation kit (Miltenyi Corp). Cells were seeded in clear bottom white -walled flat bottom 96-well plates (20,000 cells per well) in RPMI and 10% FBS. ENZA (MedChem Express) and vorinostat (MedChem Express) 10mM in DMSO and diluted with RPMI to indicated concentrations. Effects of the treatments were evaluated after 5 days using CellTiter-Glo (Promega).

### *Drug synergy assessment*

 In a 384-well plate, 500 LNCaP or LNCaP-16D cells were seeded and treated with various concentrations of ENZA (MedChemExpress, Monmouth Junction NJ, USA) and vorinostat (kindly provided by Rene Bernards, NKI). Five days later, the CellTiter Glo assay (Promega Benelux BV, Leiden, Netherlands) was performed according to the manufacturer's instruction. All the assays were performed in biological quadruplicates (n=4). All the conditions (single and combination) were normalized to non-treated condition (set at 100). SynergyFinder 2.0<sup>42</sup> was used to evaluate and plot synergistic potential using highest-single agent (HSA) synergy reference model. Response of the two cell lines to single agent vorinostat was also investigated and plotted using the normalized viability in full media (FBS) and area under the curve (AUC) method.

### *Single-cell analyses*

 Single-cell RNA-seq (GSE168669) data was used to produce UMAP visualizations of LNCaP 308 parental and LNCaP RES-B retaining cluster identities from Taavitsainen *et al.*<sup>32</sup> The genes proximal to the 657 non-responder H3K27ac sites were compiled into a gene set expression analysis to produce scores per cell with AddModuleScore function from Seurat (version 311 4.3.0). Previously identified single-cell clusters (clusters 0 to  $12^{32}$  were used in the enrichment analysis to overlap genes proximal to the 657 non-responder H3K27ac sites.

#### **Results**

# **Phase II trial of AR-targeted therapy in patients with mCRPC**

 To identify novel epigenetic biomarkers, we conducted a single-arm, open-label, phase 2 study in patients with mCRPC treated with a new line of AR targeted therapy, being a sub- investigation of the CPCT-02 biopsy protocol (NCT01855477) (Figure 1A). Between September 2014 and April 2019, a total of 64 mCRPC patients were enrolled in the trial.  Baseline characteristics are summarized in Supplementary Table 1, trial outcomes in Supplementary Table 2 and Supplementary Figure 1: Consort diagram, with in-depth description of relevant clinicopathological parameters and outcomes included in the supplementary clinical trial data section (Supplementary Data).

### **Biopsy assessment and evaluable population for biomarker discovery**

 All 64 patients had a pre-treatment biopsy from a metastatic lesion. Biopsy sites from the whole population include bone (n=19; 29.7%), lymph-nodes (n=32; 50.0%) and visceral organs (n=13; 20.3%) (Supplementary Table 1). A second biopsy (post-treatment) was taken upon disease progression for 15 patients. Biopsies with ≥30% tumor cells were further processed for downstream molecular analyses (42 and 12 for pre- and post-treatment, respectively) (Supplementary Figure 1: Consort diagram). We successfully generated ChIP- seq data for active promoter/enhancer histone modification H3K27ac —passing stringent QC requirements (See Methods) for 22 out of the 42 samples. Four (18.2%) of the pre-treatment biopsies evaluable for biomarkers, were from bone metastases, while 13 (59.1%) were from lymph-node metastases and 5 (22.7%) from visceral metastases (Supplementary Table 1). For 6 of 15 post-treatment biopsies, we obtained high quality H3K27ac ChIP-seq data. One (16.7%) of the post-treatment biopsies was from bone, 3 (50.0%) were from lymph-nodes and 2 (33.3%) were from visceral organs. One patient had both pre- and post-treatment biopsies resulting in 28 biopsy samples for further analyses from 27 unique patients. The baseline characteristics and treatment outcomes of the 22 patients who donated an evaluable pre-treatment biopsy and the 6 patients who donated an evaluable post-treatment biopsy, are summarized in Supplementary Table 1 and Supplementary Table 2, respectively. There were no significant differences in baseline age, serum PSA, the treatment outcomes, duration of treatment, PSA change from baseline, and Time to PSA Progression (TTPP) between the

 patients who donated an evaluable pre- and/or post-treatment biopsy and the whole population (Supplementary Table 1 and Supplementary Table 2). Additional clinical information and methods can be found in Supplementary Information.

 Prior to functional genomic downstream analyses, all patients were categorized for their 350 overall response, which was a composite of three outcomes:  $(1) \ge 50\%$  PSA decrease from baseline, (2) radiographic response (stable disease, partial response or complete response), and (3) longer than median TTPP. Assessment was conservative; in case a patient could not be evaluated on a particular outcome measure, it was considered as no response. All patients were evaluable for this endpoint, except for one patient (1.6%) who could not be evaluated for any of the three outcomes (Supplementary Table 2). In the whole population, 23.4% of patients scored on all three items (Response to ENZA), 37.5% of patients did not score on any item (No response to ENZA) and the remaining 37.5% of patients had inconsistent responses on the three outcome measures listed above (Intermediate response to ENZA). Of the 22 patients in the pre-treatment evaluable population, 6 (27.3%) patients had a response, 8 (36.4%) patients had an intermediate response, and 8 (36.4%) patients had no response to ENZA (Supplementary Table S2). Of the 6 patients in the post-treatment evaluable population, 2 patients had a response (33.3%), 2 patients had an intermediate response (33.3%), 1 patient had no response (16.7%) to ENZA treatment, while 1 patient was not evaluable (16.7%) (Supplementary Table S2). Based on the ChIP-seq QC parameters and clinical assessment of our trial data, 28 biopsies (22 pre- and 6 post- treatment, from 27 unique patients) with high quality ChIP-seq data are available, roughly equally sized response groups were formed, with 8 responders, 10 intermediate and 9 non-responders to treatment (one unknown) (Figure 1B).

### **Genome-wide epigenetic profiling of mCRPC**

 Apart from H3K27ac ChIP-seq data, for which we successfully generated high-quality data for 28 metastatic biopsy samples (see above), 10 FOXA1 ChIP-seq and 2 AR ChIP-seq datasets were generated on these fine needle core biopsies (Figure 1B and Supplementary Figure 1: CONSORT diagram). As all these patients received prior ADT, the low circulating testosterone levels may explain the relatively low success-rate of AR ChIP-seq (of which chromatin binding is decreased following ADT) as compared to FOXA1. For peak numbers, read counts and other relevant ChIP-seq QC parameters, see Supplementary Table 3 and Supplementary Figure 2A,B.

 All H3K27ac ChIP-seq samples were highly correlated based on genome-wide patterns (Figure 1B) indicating low inter-tumor heterogeneity, and robust technical reproducibility. As 382 expected, and in line with our previous study on multiple metastases from the same patient<sup>22</sup>. FOXA1 and AR profiles were intermingled in our unsupervised hierarchical analysis reflecting 384 the direct biological interplay between these two factors<sup>16,43</sup>. No correlation was observed with metastatic site or treatment condition/status or clinical response in the clustering with all factors (Figure 1B), nor on H3K27ac alone (Supplementary Figure 3A,B). As H3K27ac ChIP- seq data represented the largest and most-complete dataset, we decided to first focus on these samples. For H3K27ac profiles, we found comparably high-quality peaks across all three response groups, as exemplified on single locus (Figure 1C) and genome-wide scale (Figure 1D). Taken together, our data indicate the vast majority of H3K27ac sites are overlapping across sample types, irrespectively of AR-targeted therapy response.

**Distinct H3K27ac profiles identify mCRPC tumors resistant to AR-targeted therapy**

 While the total universe of H3K27ac profiles did not differ between response groups of patients, possible subsets of regions may still exist that stratify patients on outcome. To ensure that subtle differences in cut-offs and definitions of treatment response would not affect data interpretation, we performed supervised differential binding analysis<sup>44</sup> with the H3K27ac data in the most extreme treatment response groups (responder and non- responder) (Figure 2A). In total, we observed 682 H3K27ac regions that significantly differed between these response groups, with 657 sites selectively enriched in non-responder patients and merely 25 sites found selectively enriched in responders (adj.p ≤ 0.05, logFC ≥ abs|2|, Figure 2B). As expected for H3K27ac ChIP-seq, both sets of sites are predominantly found in distal intergenic regions (Supplementary Table 4). Differentially enriched peaks between responders and non-responders were robust, as exemplified for three genomic loci (Figure 2C), and quantified showing enriched signal in non-responders compared to responders across all non-responder sites (Figure 2D).

 To determine whether the 657 H3K27ac sites enriched in non-responders represent an acquired feature of mCRPC, or whether H3K27ac signal at these regions is already present in the primary disease setting and associated with aggressiveness, we re-analyzed H3K27ac ChIP-seq data from a matched case-control cohort of treatment naïve primary prostate 412 cancer patients that we reported previously<sup>30</sup>. We observed no difference in H3K27ac signal at these sites based on case/control status (Supplementary Figure 4A), nor on Gleason score (7 versus 9) (Supplementary Figure 4B) while typical signal for known primary-specific AR 415 binding sites was clearly present<sup>16</sup> (Supplementary Figure 4C). Further supporting the notion that these regions are acquired in the treatment-resistance metastatic setting, we observed stronger signal in the non-responder metastatic samples (this study) compared with treatment 418 naïve metastasis samples and previously reported primary prostate cancer samples<sup>18</sup> as well

419 as healthy prostate tissue<sup>18</sup> (Supplementary Figure 4D). Together, these data suggest that the resistance-associated H3K27ac sites represent an mCRPC-unique feature of resistance to AR-targeted therapy. Collectively, our data indicate that a specific subset of H3K27ac sites enables us to stratify mCRPC patients for an outcome to third generation AR inhibitor treatment.

# **Resistance-associated H3K27ac profiles predict response to castration in mCRPC patient-derived xenografts**

 H3K27ac profiling in clinical samples allowed us to stratify tumors from mCRPC patients on response to AR-targeted therapeutics. To independently validate these findings and to explore the potential for stratification beyond our own study, we next investigated an existing 430 H3K27ac ChIP-seq dataset that we previously reported for mCRPC PDX samples<sup>18</sup>. The PDX models were generated from CRPC prostate cancer tumors, and represent metastatic samples from multiple metastatic sites, including adrenal glands, ascites, bladder, bone, 433 bowel, lymph-node and liver<sup>36</sup>. Originally, to determine the hormone-dependency of the PDX tumor growth, PDX tumors were grown in testosterone proficient male mice, after which the animals were either castrated or left intact (see overview in Figure 3A).

 To evaluate whether the PDX tumors would classify according to the 657 non-responder H3K27ac sites, we plotted H3K27ac ChIP-seq data for these sites in 15 available PDX samples (Figure 3B and Figure 3C). Interestingly, 7 PDXs (45%) displayed strong H3K27ac signal at these regions, while the remaining 8 PDX samples (55%) displayed weak signal at these sites; with no significant global differences between these two groups of samples (Supplementary Figure 5). Integrating these cistromic data with the *in vivo* response-to-castration data showed that a strong H3K27ac signal is correlated with less tumor regression

 upon castration of the animals (Figure 3D, raw data Supplementary Figure 6). In contrast, PDXs with weak H3K27ac signal at our clinically observed H3K27ac non-responder sites, showed tumor regression upon animal castration. Importantly, using single-cell RNA-seq data (scRNA-seq) from prostate cancer cell lines, we find genes associated with our clinically observed H3K27ac non-responder sites as significantly enriched in a cell cluster that 449 selectively appears in LNCaP-derived ENZA-resistant cells<sup>32</sup> (cluster 3) (Figure 3E). After long-term treatment with ENZA, cluster 3 enriched mainly for LNCaP RES-B resistant cells and only partially for RES-A cells. In fact, in LNCaP RES-B cells cluster 3 was expanded compared to parental cells and also compared to RES-A, indicating that these cells drive resistance-specific biology. In addition, average gene expression of genes associated with H3K27ac non-responder sites was linked with cluster 3 expansion (Figure 3F). Interestingly, scATAC-seq (single cell Assay for Transposase-Accessible Chromatin using sequencing) 456 clusters identified previously to be associated with scRNA-seq cluster  $3^{32}$ , indicated no selective enrichment of known transcription factors involved in treatment-mediated chromatin reprogramming in prostate cancer. Together, these data illustrate that distinct H3K27ac signals stratifying patients for response to AR blockade, and we validated the same profiles in mCRPC PDX models and at the single-cell level in models of ENZA resistance.

## **Driver identification for resistance to AR inhibition in mCRPC**

 Using the combined datastreams of H3K27ac ChIP-seq and response-to-castration in PDX models, we successfully validated our 657 H3K27ac sites as indicative for unresponsiveness to hormonal intervention in mCRPC. As no selective transcription factor usage was enriched upon integrating scRNA-seq and scATAC-seq data, we conclude that possibly multiple factors -or proteins binding the genome without direct DNA recognition motif, drive resistance. Therefore, instead of TF motif analyses, we used GIGGLE; a genomics search engine that

 queries previously-reported protein/chromatin occupancy datasets and ranks the significance of genomic loci shared between query and a database of regions<sup>35</sup>. Specifically, we analyzed an extensive database of ChIP-seq experiments from prostate tissue-derived cell lines and 472 prostate cancer cell lines<sup>34,45</sup> (Supplementary Table 5) to explore which DNA-associated proteins bind at our defined non-responder H3K27ac sites (Figure 4A)*.* This analysis identified multiple factors previously reported to drive resistance to ENZA treatment or 475 castration, including  $HNF4G^{46}$ , NR3C1 (glucocorticoid receptor)<sup>47-49</sup> and  $FOXA1^{50}$  (Supplementary Table 5). To clinically validate the cell line-based GIGGLE enrichment data, we next analyzed the FOXA1 ChIP-seq data from our mCRPC samples, separating the non- responder (n=4) and responder (n=3) samples. These analyses revealed selective enrichment of FOXA1 binding at the 657 non-responder H3K27ac sites in mCRPC samples from non-responder patients, confirming the GIGGLE enrichment data (Figure 4B).

 Next, we sought to explore the functional involvement of top-enriched factors (Supplementary Table 5) in driving resistance to AR blockade (essential genes in our setting), by designing and performing a focused siRNA screen (4 pooled siRNAs per target (genes with median GIGGLE combo enrichment score >20)) to target genes in two cell line models of castration 486 resistance (LNCaP-Abl<sup>38</sup> and LNCaP-16D $^{37}$ ) as well as a model of ENZA resistance (LNCaP-487 Enz<sup>R</sup>)<sup>40</sup> (Figure 4C). From the pooled siRNA experiments, eleven hits that significantly diminished proliferation in at least two out of three cell lines (Figure 4D), relative to siControl and were identified as top-enriched factors in the GIGGLE analysis, were selected for deconvolution experiments in castration-resistant LNCaP-16D. Single siRNAs were tested individually, in which decreased cell proliferation potential observed for at least 2 out of 4 siRNAs was considered a validated hit. These analyses identified factors previously described as critical in driving resistance to both ENZA and castration in prostate cancer cell

494 Iines: FOXA1<sup>50</sup> and GATA2<sup>51</sup> (Figure 4E, Supplementary Figure 7). Furthermore, two factors 495 previously reported to be associated with castration resistance, but not studied before for 496 their potential involvement in driving resistance to ENZA, were identified: HDAC3<sup>52</sup> and 497 ASH2L<sup>53</sup>. Collectively, these studies revealed potential drivers and possible drug targets to 498 treat castration-resistant prostate cancer.

499

# 500 **Histone deacetylase (HDAC) inhibition synergizes with enzalutamide to block mCRPC**  501 **cell growth**

 Computational analyses and perturbation studies identified five factors of potential therapeutic interest. As transcription factors are considered challenging drug targets, we focused on HDAC3 for further downstream studies. HDAC3 has previously been reported as therapeutic target in castration-resistant prostate cancer<sup>52</sup>, but remains unexplored in the ENZA-resistant setting. Highly selective HDAC3 inhibitors have been described but have not 507 been explored for efficacy and tolerability in clinical trials<sup>54</sup>. Less specific HDAC inhibitors are well characterized and clinically implicated in the treatment of several cancer types, including 509 vorinostat in the treatment of cutaneous T-cell lymphoma<sup>55</sup>. Vorinostat has been previously 510 reported to block proliferation of prostate cancer cells<sup>56</sup> and to synergize with the AR-511 antagonist bicalutamide<sup>57</sup>. Consequently, HDAC inhibitors have the potential to overcome 512 resistance to established mCRPC treatments, including AR targeted drugs<sup>58</sup>. A significant increase in sensitivity to HDAC inhibition was observed in castration-resistant LNCaP-16D cells relative to hormone-sensitive parental LNCaP cells (Supplementary Figure 8. Importantly, in both LNCaP cells and LNCaP-16D cells, vorinostat synergized with ENZA (Figure 4F, Supplementary Figure 9A*)*. To further establish therapeutic proof-of-concept, subcutaneous PDX tumors were dissociated and treated *ex vivo* with increasing concentrations of ENZA, vorinostat, or both, which allowed us to determine synergy (Figure  4G). In agreement with the cell line-based results, *ex vivo* drug response in mCRPC PDXs confirmed synergistic interactions between vorinostat and ENZA (Figure 4G, Supplementary Figure 9A, 9B).

 In summary, by performing H3K27ac ChIP-seq analyses of metastatic lesions from mCRPC patients, we identified an epigenetics-based classification for response prediction to AR- targeted therapy which we successfully validated in mCRPC PDX mouse models. These analyses revealed drivers for resistance to AR-targeted therapeutics, and identified ENZA in combination with pan-HDAC inhibitor vorinostat as a novel synergistic and highly effective drug combination for the treatment of castration-resistant prostate cancer.

### **Discussion**

 The clinical significance of the non-protein coding genome in prostate cancer is rapidly gaining attention. Recently, whole-genome sequencing of primary prostate cancer 533 specimens revealed enrichment of somatic mutations in AR chromatin binding sites<sup>59,60</sup>, a 534 subset of which functionally affected enhancer activity<sup>15</sup>. Not only in primary prostate cancer but also in the mCRPC setting, non-coding somatic alterations have been reported, including 536 amplification of enhancer elements that regulate expression of  $AR^{61,62}$ , HOXB13<sup>18</sup> and FOXA1<sup>18</sup>. In addition to somatic alterations in the primary DNA sequence or copy number, modifications in epigenetic regulatory elements are proving crucial in prostate cancer development and progression. Furthermore, extensive epigenetic reprogramming and AR 540 enhancer plasticity have been related to tumorigenesis<sup>15,16</sup> and progression<sup>18</sup>, as well as therapy resistance<sup>17</sup>. To date, deviations in enhancer regulation have not been extensively studied in castration-resistant disease and have not been explored in the context of a controlled clinical trial. Here, we interrogated the epigenome in relation to AR-targeted  therapy response in mCRPC patients. Within our clinical cohort, epigenetic features revealed a robust classification scheme predicting response to treatment. These findings additionally revealed potential drivers of resistance as well as novel therapeutic drug combinations to combat castration-resistant disease.

549 While ENZA improves outcome in patients with mCRPC $12,13$ , a significant proportion of mCRPC patients experience no response to AR-targeting treatment due to intrinsic resistance mechanisms. Supporting the notion of a pre-existing treatment resistance patient population, we found that H3K27ac profiles in mCRPC tumors remained unaltered following ENZA treatment. These data suggest that these cancers were already resistant prior to drug exposure, harboring epigenetic programs that support AR-independent cellular growth. In contrast, most previously described resistance mechanisms appeared to be treatment-556 induced, including AR mutations<sup>63-65</sup> and amplification<sup>40</sup>, GR upregulation<sup>47-49</sup> or enrichment of HNF4G<sup>46</sup>. As the tumor samples we analyzed were already relapsed after prior therapies and developed castration resistance, it is plausible that the induction of the abovementioned resistance mechanisms occurred before our samples were taken. At the single-cell level, genes associated with our H3K27ac non-responder sites were significantly enriched in an ENZA-resistance-associated cluster which expands after long-term treatment<sup>32</sup>, indicating that the acetylated regions we have identified – and associated genes – are important in driving therapeutic resistance in a subset of tumors. These results may jointly point towards the induction of divergent castration resistance mechanisms, which either sustain hormone- dependency (as in the case for our 'responder' population) or diverge towards complete hormone-independence (our 'non-responder' population), in which other transcription factors compensate for the lack of AR activity.

 Apart from the hormone receptor family, transcription factors are generally considered challenging drug targets and potential other therapeutic strategies – such as epigenetic drugs – may prove of clinical benefit for these cases. Along these lines, for three of our hits: NKX3- 571 1, FOXA1 and GATA2, specific inhibitors are yet to be developed. Recently, indirect small 572 molecule inhibition of FOXA1 has been described, by means of targeting EZH2 $^{66}$  and LSD1 $^{67}$ , presenting a potential direct therapeutic avenue in this setting.

 As HDAC3 expression has been shown to be critical for AR-driven transcriptional programs  $575 -$  both in hormone-sensitive and castration-resistant cell line models<sup>68</sup> – we chose to further study the potential benefit of HDAC inhibition as a therapeutic strategy in mCRPC. Our data reveal that HDAC3 is also critically involved in resistance to AR-targeted therapeutics in the mCRPC setting, and prove therapeutic proof-of-concept of a synergistic drug-drug interaction between ENZA and the pan-HDAC inhibitor vorinostat, both in cell line models and mCRPC PDX-derived explants. This drug has been clinically approved in the treatment of cutaneous T cell lymphomas and also shown promise as a therapeutic strategy in advanced non-small 582 cell lung cancer<sup>69</sup>. Although, vorinostat showed no activity as a single agent in mCRPC patients, a phase 2 trial into the combination of the non-selective HDAC inhibitor panobinostat 584 and the AR targeted drug bicalutamide in 55 patients, showed promising results<sup>70,71</sup>. Common drug-related serious adverse events such as thromboembolic events associated 586 with vorinostat are of concern<sup>55</sup>, but may be avoided with the likely lower concentrations used in a combination with ENZA.

**Conclusions**

All rights reserved. No reuse allowed without permission.

- Based on our results, new clinical trials for testing vorinostat or other HDAC inhibitors in
- conjunction with ENZA for mCRPC patients would be justified, since novel highly-effective
- drug-drug combinations are urgently needed to combat this deadly disease.
- 
- 
- **Declarations**
- *Ethical Approval and Consent to Participate*

 The trial was approved by the institutional review board of the Netherlands Cancer Institute, written informed consent was signed by all participants enrolled in the study, and all research was carried out in accordance with relevant guidelines and (inter-)national and ethical standards. Within the General Data Protection Regulation, patients always had the opportunity to object or actively consent to the (continued) use of their personal data and biospecimens for research purposes.

- 
- *Consent for Publication*
- All authors have read the manuscript and consent to publication.
- 
- *Availability of Supporting Data*

 Raw ChIP-sequence data are deposited in the European Genome-Phenome Archive (EGAS00001006161)

- 
- *Competing Interests*

WZ and AMB received research funding from Astellas Pharma for the work performed in this

- manuscript. All other authors declare no competing interests.
- 
- *Funding*

 This work is supported by Astellas Pharma Europe BV (WZ, AMB), The Prostate Cancer Foundation (Challenge Award – MLF, MMP, WZ, TMS); The United States Department of Defense (Idea Award, PC180367 – MLF, MMP, WZ); Oncode Institute (WZ), KWF Dutch Cancer Society / Alpe d'HuZes (10084 – WZ, AMB and 7080 – AMB, MSvdH, LW), PNW Prostate Cancer SPORE (P50CA097186, P01CA163227 – EC) and Craig Watjen Memorial funds (EC); Academy of Finland (#349314 – AU) and Norwegian Cancer Society (#198016- 2018 – AU); S. H. and M.N. Academy of Finland (#312043, #310829).

#### All rights reserved. No reuse allowed without permission.

## *Authors' Contributions*

 TMS, YZ, SP, WZ and AMB wrote the main manuscript text. TMS, YZ, SP, KS, HMN, LGB, SH, YK, JK, SL, SS, CL, VvdN, JS, BM, GJ, GFJLvL, AU, RLB, EC, WZ and AMB prepared and analyzed data for all figures and tables. All other authors reviewed the manuscript. 

*Acknowledgments*

 The authors gratefully acknowledge the patients and the families of patients who contributed to this study. We thank the NKI Genomics Core Facility, Core Facility Molecular Pathology and Biobanking, Research High Performance Computing Facility, Scientific Information Service for their excellent technical support and all group members from the Zwart, Bergman and Corey labs for highly constructive feedback and suggestions. The authors thank the A.U. Norwegian Cancer Society, Academy of Finland and Cancer Foundation Finland, S.H. and M.N. Academy of Finland and Sigrid Jusélius Foundation, Finnish Cancer Institute.

- 
- *Authors' Information*

 \*Tesa M. Severson: Divisions of Oncogenomics and Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands

 \*Yanyun Zhu: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands

 \*Stefan Prekovic: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands

- Karianne Schuurman: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands
- Holly M. Nguyen: Department of Urology, University of Washington, Seattle, WA, USA
- Lisha G. Brown: Department of Urology, University of Washington, Seattle, WA, USA
- Sini Hakkola: Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
- 
- Yongsoo Kim: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Present working address: Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 
- Jeroen Kneppers: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands
- Simon Linder: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands
- 

All rights reserved. No reuse allowed without permission.

 Suzan Stelloo: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Present working address: Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University, Nijmegen, 6525 GA Nijmegen, the Netherlands.

 Cor Lieftink: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands

 Michiel van der Heijden: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

- 
- Matti Nykter: Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
- 
- Vincent van der Noort: Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 
- Joyce Sanders: Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 

- Ben Morris: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- Guido Jenster: Department of Urology, Erasmus MC, Rotterdam, the Netherlands
- Geert JLH van Leenders: Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands
- Mark Pomerantz: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
	-
	- Matthew L. Freedman: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, The Eli and Edythe L. Broad Institute, Cambridge, MA, USA
	- Roderick L. Beijersbergen: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
	-

- Alfonso Urbanucci: Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland, Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- 
- Lodewyk Wessels: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands, Department of EEMCS, Delft University of Technology, Delft, The Netherlands
- 
- Eva Corey: Department of Urology, University of Washington, Seattle, WA, USA
- 

All rights reserved. No reuse allowed without permission.

 #Wilbert Zwart: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands, Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands

 #Andries M. Bergman: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

\*shared first authors



- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

# **References**

- 1 Ferlay, J. *et al.* Cancer statistics for the year 2020: An overview. *Int J Cancer* (2021). https://doi.org:10.1002/ijc.33588
- 2 Mottet, N. *et al.* EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol* **79**, 243-262 (2021). https://doi.org:10.1016/j.eururo.2020.09.042
- 3 Freedland, S. J. *et al.* Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. *JAMA* **294**, 433-439 (2005). https://doi.org:10.1001/jama.294.4.433
- 4 Kupelian, P. A., Mahadevan, A., Reddy, C. A., Reuther, A. M. & Klein, E. A. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. *Urology* **68**, 593-598 (2006). https://doi.org:10.1016/j.urology.2006.03.075
- 5 Roehl, K. A., Han, M., Ramos, C. G., Antenor, J. A. & Catalona, W. J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. *J Urol* **172**, 910-914 (2004). https://doi.org:10.1097/01.ju.0000134888.22332.bb
- 6 Harris, W. P., Mostaghel, E. A., Nelson, P. S. & Montgomery, B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol* **6**, 76-85 (2009). https://doi.org:10.1038/ncpuro1296
- 7 van Royen, M. E. *et al.* Compartmentalization of androgen receptor protein-protein interactions in living cells. *J Cell Biol* **177**, 63-72 (2007). https://doi.org:10.1083/jcb.200609178
- 8 Lupien, M. *et al.* FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. *Cell* **132**, 958-970 (2008). https://doi.org:10.1016/j.cell.2008.01.018

All rights reserved. No reuse allowed without permission.

- 9 Wang, Q. *et al.* Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell* **138**, 245-256 (2009). https://doi.org:10.1016/j.cell.2009.04.056
- 10 Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to genome-wide predictions. *Nat Rev Genet* **15**, 272-286 (2014). https://doi.org:10.1038/nrg3682
- 11 Kim, T. K. & Shiekhattar, R. Architectural and Functional Commonalities between Enhancers and Promoters. *Cell* **162**, 948-959 (2015). https://doi.org:10.1016/j.cell.2015.08.008
- 12 Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* **367**, 1187-1197 (2012). https://doi.org:10.1056/NEJMoa1207506
- 13 Beer, T. M. *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* **371**, 424-433 (2014). https://doi.org:10.1056/NEJMoa1405095
- 14 Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. & Prekovic, S. Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. *Endocr Relat Cancer* **26**, R31-R52 (2018). https://doi.org:10.1530/ERC-18-0289
- 15 Mazrooei, P. *et al.* Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. *Cancer Cell* **36**, 674-689 e676 (2019). https://doi.org:10.1016/j.ccell.2019.10.005
- 16 Pomerantz, M. M. *et al.* The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. *Nat Genet* **47**, 1346-1351 (2015). https://doi.org:10.1038/ng.3419
- 17 Stelloo, S. *et al.* Androgen receptor profiling predicts prostate cancer outcome. *EMBO Mol Med* **7**, 1450-1464 (2015). https://doi.org:10.15252/emmm.201505424
- 18 Pomerantz, M. M. *et al.* Prostate cancer reactivates developmental epigenomic programs during metastatic progression. *Nat Genet* **52**, 790-799 (2020). https://doi.org:10.1038/s41588-020-0664-8
- 19 Scher, H. I. *et al.* Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol* **34**, 1402- 1418 (2016). https://doi.org:10.1200/JCO.2015.64.2702
- 20 Schwartz, L. H. *et al.* RECIST 1.1-Update and clarification: From the RECIST committee. *Eur J Cancer* **62**, 132-137 (2016). https://doi.org:10.1016/j.ejca.2016.03.081
- 21 Singh, A. A. *et al.* Optimized ChIP-seq method facilitates transcription factor profiling in human tumors. *Life Sci Alliance* **2**, e201800115 (2019). https://doi.org:10.26508/lsa.201800115
- 22 Severson, T. M. *et al.* Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases. *Mol Oncol* **15**, 1942-1955 (2021). https://doi.org:10.1002/1878-0261.12923
- 23 Severson, T. M. *et al.* Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. *Nat Commun* **9**, 482 (2018). https://doi.org:10.1038/s41467-018-02856-2
- 24 Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079 (2009). https://doi.org:10.1093/bioinformatics/btp352
- 25 Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137 (2008). https://doi.org:10.1186/gb-2008-9-9-r137
- 26 Marinov, G. K., Kundaje, A., Park, P. J. & Wold, B. J. Large-scale quality analysis of published ChIP-seq data. *G3 (Bethesda)* **4**, 209-223 (2014). https://doi.org:10.1534/g3.113.008680
- 27 Ramirez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res* **44**, W160-165 (2016). https://doi.org:10.1093/nar/gkw257
- 28 Lopez-Delisle, L. *et al.* pyGenomeTracks: reproducible plots for multivariate genomic datasets. *Bioinformatics* **37**, 422-423 (2021). https://doi.org:10.1093/bioinformatics/btaa692
- 29 Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. *Bioinformatics* **31**, 2382-2383 (2015). https://doi.org:10.1093/bioinformatics/btv145
- 30 Stelloo, S. *et al.* Integrative epigenetic taxonomy of primary prostate cancer. *Nat Commun* **9**, 4900 (2018). https://doi.org:10.1038/s41467-018-07270-2
- 31 Handle, F. *et al.* Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. *Sci Rep* **9**, 13786 (2019). https://doi.org:10.1038/s41598-019-50220-1

All rights reserved. No reuse allowed without permission.

- 32 Taavitsainen, S. *et al.* Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. *Nat Commun* **12**, 5307 (2021). https://doi.org:10.1038/s41467-021-25624-1
- 33 Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587 e3529 (2021). https://doi.org:10.1016/j.cell.2021.04.048
- 34 Zheng, R. *et al.* Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. *Nucleic Acids Res* **47**, D729-D735 (2019). https://doi.org:10.1093/nar/gky1094
- 35 Layer, R. M. *et al.* GIGGLE: a search engine for large-scale integrated genome analysis. *Nat Methods* **15**, 123-126 (2018). https://doi.org:10.1038/nmeth.4556
- 36 Nguyen, H. M. *et al.* LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular 820 Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. *Prostate* **77**, 654-671 (2017). https://doi.org:10.1002/pros.23313
- 37 Bishop, J. L. *et al.* The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. *Cancer Discov* **7**, 54-71 (2017). https://doi.org:10.1158/2159-8290.CD-15-1263
- 38 Culig, Z. *et al.* Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. *Br J Cancer* **81**, 242-251 (1999). https://doi.org:10.1038/sj.bjc.6690684
- 39 Kim, S. *et al.* PEG10 is associated with treatment-induced neuroendocrine prostate cancer. *J Mol Endocrinol* **63**, 39-49 (2019). https://doi.org:10.1530/JME-18-0226
- 40 Kregel, S. *et al.* Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. *Oncotarget* **7**, 26259-26274 (2016). https://doi.org:10.18632/oncotarget.8456
- 833 41 Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput screening data analysis. *Nat Biotechnol* **24**, 167-175 (2006). https://doi.org:10.1038/nbt1186
- 42 Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. *Nucleic Acids Res* **48**, W488-W493 (2020). https://doi.org:10.1093/nar/gkaa216
- 43 Stelloo, S. *et al.* Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. *Oncogene* **37**, 313-322 (2018). https://doi.org:10.1038/onc.2017.330
- 44 Ross-Innes, C. S. *et al.* Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature* **481**, 389-393 (2012). https://doi.org:10.1038/nature10730
- 45 Mei, S. *et al.* Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. *Nucleic Acids Res* **45**, D658-D662 (2017). https://doi.org:10.1093/nar/gkw983
- 46 Shukla, S. *et al.* Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. *Cancer Cell* **32**, 792-806 e797 (2017). https://doi.org:10.1016/j.ccell.2017.10.008
- 47 Li, J. *et al.* Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. *Elife* **6** (2017). https://doi.org:10.7554/eLife.20183
- 48 Shah, N. *et al.* Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. *Elife* **6** (2017). https://doi.org:10.7554/eLife.27861
- 49 Puhr, M. *et al.* The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. *Clin Cancer Res* **24**, 927-938 (2018). https://doi.org:10.1158/1078-0432.CCR-17-0989
- 50 Jones, D. *et al.* FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. *Oncotarget* **6**, 29782-29794 (2015). https://doi.org:10.18632/oncotarget.4927
- 51 Chaytor, L. *et al.* The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer. *Mol Cancer Res* **17**, 1264-1278 (2019). https://doi.org:10.1158/1541-7786.MCR-18-1231
- 52 McLeod, A. B. *et al.* Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. *Prostate* **78**, 266-277 (2018). https://doi.org:10.1002/pros.23467

All rights reserved. No reuse allowed without permission.

- 53 Malik, R. *et al.* Targeting the MLL complex in castration-resistant prostate cancer. *Nat Med* **21**, 344- 352 (2015). https://doi.org:10.1038/nm.3830
- 54 Liu, J. *et al.* Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group. *ACS Med Chem Lett* **11**, 2476-2483 (2020). https://doi.org:10.1021/acsmedchemlett.0c00462
- 55 Olsen, E. A. *et al.* Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol* **25**, 3109-3115 (2007). https://doi.org:10.1200/JCO.2006.10.2434
- 56 Butler, L. M. *et al.* Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. *Cancer Res* **60**, 5165-5170 (2000).
- 57 Marrocco, D. L. *et al.* Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. *Mol Cancer Ther* **6**, 51-60 (2007). https://doi.org:10.1158/1535-7163.MCT-06-0144
- 58 Biersack, B., Nitzsche, B. & Hopfner, M. HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer. *Cancer Drug Resist* **5**, 64-79 (2022). https://doi.org:10.20517/cdr.2021.105
- 59 Morova, T. *et al.* Androgen receptor-binding sites are highly mutated in prostate cancer. *Nat Commun* **11**, 832 (2020). https://doi.org:10.1038/s41467-020-14644-y
- 60 Zhou, S. *et al.* Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. *Nat Commun* **11**, 441 (2020). https://doi.org:10.1038/s41467-020-14318-9
- 61 Takeda, D. Y. *et al.* A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. *Cell* **174**, 422-432 e413 (2018). https://doi.org:10.1016/j.cell.2018.05.037
- 62 Quigley, D. A. *et al.* Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell* **174**, 758-769 e759 (2018). https://doi.org:10.1016/j.cell.2018.06.039
- 63 Prekovic, S. *et al.* The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. *Mol Cancer Ther* **15**, 1702-1712 (2016). https://doi.org:10.1158/1535-7163.MCT-15- 0892
- 64 Korpal, M. *et al.* An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). *Cancer Discov* **3**, 1030-1043 (2013). https://doi.org:10.1158/2159- 8290.CD-13-0142
- 65 Sun, C. *et al.* Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. *Oncogene* **25**, 3905-3913 (2006). https://doi.org:10.1038/sj.onc.1209424
- 66 Park, S. H. *et al.* Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. *Sci Adv* **7** (2021). https://doi.org:10.1126/sciadv.abe2261
- 67 Gao, S. *et al.* Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. *Nat Genet* **52**, 1011-1017 (2020). https://doi.org:10.1038/s41588-020-0681-7
- 68 Welsbie, D. S. *et al.* Histone deacetylases are required for androgen receptor function in hormone- sensitive and castrate-resistant prostate cancer. *Cancer Res* **69**, 958-966 (2009). https://doi.org:10.1158/0008-5472.CAN-08-2216
- 69 Gray, J. E. *et al.* Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. *Clin Cancer Res* **25**, 6623-6632 (2019). https://doi.org:10.1158/1078-0432.CCR-19- 1305
- 70 Bradley, D. *et al.* Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the 906 Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. *Cancer* **115**, 5541-5549 (2009). https://doi.org:10.1002/cncr.24597
- 71 Ferrari, A. C. *et al.* Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. *Clin Cancer Res* **25**, 52-63 (2019). https://doi.org:10.1158/1078- 0432.CCR-18-1589
- 

All rights reserved. No reuse allowed without permission.

- 
- 

#### **Figure Legends**

### **Figure 1: Clinical trial design and ChIP-seq data collection**

- A. Setup of the clinical trial. Patients with mCRPC are enrolled in the study, and an imaging-guided biopsy is taken prior to onset of enzalutamide treatment. One patient in the study was treated with abiraterone.
- B. Correlation heatmap of ChIP-seq data (50kb bins across the genome, Pearson correlation) for H3K27ac, AR and FOXA1 among all mCRPC samples (n=40). Colors bars indicate ChIP factors: AR (light blue), FOXA1 (light green) and H3K27ac (dark green), tissue of sample origin: lymph-node (grey), visceral organ (yellow) and bone (dark green), treatment: abiraterone (Abi), salmon)) and enzalutamide (ENZA), brown)), condition of the sample: pre-treatment (purple) and post-treatment (orange), and treatment response: non-responder (dark purple), responder (pink), intermediate (blue) and unknown (black outline).
- C. Snapshot of H3K27ac ChIP-seq (n=28) in different treatment response groups: responders (pink), non-responders (purple), unknown ((unk.), black outline) and intermediate (blue). The read counts (left) and genomic coordinates (bottom) are indicated.
- D. Principal Component Analysis using normalized read counts in all peaks in H3K27ac ChIP-seq data (n=73039) from all samples (n=28). Samples labeled according to responders (pink), non-responders (purple), intermediate (blue) or unknown (white).
- 

 **Figure 2: Distinct H3K27ac profiles stratify mCRPC patients on response to AR inhibition**

 A. Differentially enriched regions from H3K27ac ChIP-seq data visualized by volcano 938 plot (n=73039). Regions marked by blue dots were significant (DiffBind DESeq2 two-939 tailed adjusted p-value  $\leq$  0.05, logFC  $\geq$  abs|2|) (n=848); all other regions are shown with hexbin density to avoid over-plotting (n=72191). Each data point density tile (hexagon) represents density of data within the tile from low (light grey) to high (black). B. Heatmap showing normalized read count of H3K27ac data in significantly differentially 943 bound regions (DiffBind DESeq2 two-tailed adjusted p-value  $\leq$  0.05, logFC  $\geq$  abs|2|) (n=848) in responder (n=8) and non-responder samples (n=9). Colors bars indicate tissue of sample origin: lymph-node (grey), visceral organ (yellow) and bone (dark green), treatment: abiraterone (Abi), salmon)) and enzalutamide (ENZA), brown)), condition of the sample: pre-treatment (purple) and post-treatment (orange) and treatment response: non-responder (dark purple) and responder (pink).

- C. Individual snapshot of H3K27ac enriched differently in 3 responder patients (pink) and 3 non-responder patients (purple) as examples. The read counts and genomic coordinates are indicated (top right and bottom, respectively).
- D. Average H3K27ac read count profiles of all merged data for responder patients (pink, n=8) and all merged non-responder patients (purple, n=9) at the 657 non-responder enriched sites (±5 kb from the peak center). Shading indicates standard-error of the data.
- 

# **Figure 3: mCRPC PDX validations of resistance-associated H2K27ac regions**

 A. Overview of the PDX models setup. Prostate cancer samples from mCRPC patients were obtained and implanted into the mouse to establish PDXs. These PDXs were characterized previously with their response to castration by the change of tumor volume.

 B. Heatmap depicting raw read counts of H3K27ac ChIP-seq signal from PDX samples at the non-responder enriched 657 H3K27ac regions, identified from the mCRPC patient samples (±5 kb from the peak center ).

- C. Average H3K27ac read count profiles of all PDX merged data for samples with weak (grey, n=8) and strong (black, n=7) signal in the non-responder 657 H3K27ac regions. (±5 kb from the peak center). Shading indicates standard-error of the data.
- D. Box plots depicting doubling time of PDX models estimated using exponential (Malthusian) growth model (y-axis) by group (x-axis). The central mark indicates the 970 median, and the bottom and top edges of the box indicate the  $25<sup>th</sup>$  and  $75<sup>th</sup>$  percentiles, respectively. The maximum whisker lengths are specified as 1.5 times the interquartile range. All individual values are depicted as circles colored by PDX model (strong H3K27ac – Castration: n=57, strong H3K27ac – Control: n=45, weak H3K27ac – Castration: n=71, weak H3K27ac – Control: n=73). Table below indicates the p-values obtained for one-way ANOVA followed by Tukey HSD test for all combinations.
- 976 E. Polar plot reporting the  $-10^*$ log<sub>10</sub>(p-values) (Fisher's exact test) of gene overlap enrichment tests between genes associated with H3K27ac non-responder regions and LNCaP scRNA-seq cluster marker genes. Color indicates strength of significance from low (pink) to high (red).
- F. Uniform manifold approximation and projection (UMAP) visualization showing the average gene expression score of genes associated with H3K27ac non-responder regions in the parental LNCaP (left) and the ENZA-Resistant, RES-B (right) single cells. Original scRNA-seq clusters (0-12) are superimposed on each plot.

 **Figure 4: Characterization of the non-responder enriched H3K27ac sites reveals drivers of resistance**

987 A. Enrichment analysis to determine significant overlap of 657 H3K27ac non-responder 988 sites with publicly available ChIP-seq data for factors previously studied in prostate cancer cell lines (n=863). Graph shows median enrichment score for each factor (GIGGLE combo score, indicating low to high significant enrichment score (Fisher's exact two-tailed test and odds-ratio)). Factors are ordered by highest score (enrichment) in the dataset with text shown in those with median enrichment score > 100.

- B. Average FOXA1 read count profiles of merged data, at the 657 non-responder enriched H3K27ac sites (±5 kb from the peak center), comparing responders (pink, 996 https://edu.fr/ n=8) and non-responders (purple, n=9). Shading indicates standard-error of the data.
- C. Setup of siRNA screen to identify factors critical of prostate cancer cell line viability, resistant to androgen ablation or enzalutamide treatment.
- D. Screen results for pooled siRNAs, showing decreased viability of prostate cancer cell 1000  $\blacksquare$  line models LNCaP-Abl (left), LNCaP-EnzR (middle) and LNCaP-16D (right). Cell viability was determined by CellTiter-Blue, and data are normalized over siControl. Bars indicate mean values ± SD (n≥2).  Adjusted P values (padj) were determined by two-sided t-test with multiple testing correction (Benjamini-Hochberg method). Statistically significant conditions (padj <0.05) are shown in red.
- E. siRNA deconvolution experiment, separately analyzing each individual siRNA for the 11 remaining hits in LNCaP-16D cells on cell viability. Cell viability was determined by CellTiter-Blue and data are normalized over siControl. Bars indicate mean values ± SD (n≥3). Adjusted P values determined as above. Statistically significant conditions (padj <0.05) are shown in red.
- F. Enzalutamide-vorinostat drug synergy analyses for LNCaP (top) and LNCaP-16D (bottom) based on viability experiments performed after 5 days of treatment.



- **Supplemental File 1:**
- Contains 9 Supplementary Figures and 4 Supplementary Tables
- 
- **Supplemental File 2:**
- Contains additional clinical trial information

Figure 1: Clinical trial design and ChilP-segudata collection preprint (Which was not certified by peer review) is the asseming teated medRying medRxiv a license to display the preprint in medRxiv preprint doi; [https://doi.org/10.1101/2023.02.24.23286403;](https://doi.org/10.1101/2023.02.24.23286403) this version posted February 24, 2023. The copyright holder for this





●

Principal Component #1 [65%]

−0.21 −0.20 −0.19 −0.18 −0.17 −0.16

chr19 51,300 51,400 51,500 Kb

kа.

0 83.9 0 0 40.4

# Figure 2: Differential binding analysis of H3K27ac data for response status



D

C

3:55320000- 55330000

1:247670000- 247682000

regions significantly enriched in non-responders responders 0-25  $0-40$   $0-55$ 0-17 0-17 0-17 والأسطاء ستنشاد

> 7:122950000- 122970000

46748000

13:46744000- 14:99728000- 5:139230000-

13970000

99740000

## 6 non-responders responders 5 4 read count read count 3 2 1 0 -5.0kb 5.0Kb

# Figure 3: mCRPC PDX and scRNA-seq validations of resistance-associated H3K27ac regions



of resistance  $A$  B  $NR3C1$   $\bullet$ 4 TOP1 O non-responders 400 responders 3 HNF4G<br><mark>§ዎጷል</mark> ቃራ medRxiv preprint doi: [https://doi.org/10.1101/2023.02.24.23286403;](https://doi.org/10.1101/2023.02.24.23286403) this version posted February 24, 2023. The copyright holder for thisMedian enrichment score 300 read count Median enrichment score preprint (which was not certified by peer review) splote author/funder, who has granted medRxiv a license to display the preprint in ewgraphe author/runder, who has grand<br>SUMO2 of perpetuity. perpetuity. All rights reserved. No reuse allowed without permission. 200 TLE3 OPPIAS1 ● HOXB13 1 AR **©** GATA2<br>HDAC3 100  $\Omega$ ● -5.0kb 5.0Kb ●● ●● 0 0 20 40 60 Ranked Factors C D LNCaP-Abl LNCaP-EnzaR LNCaP-16D Reverse siRNA library transfection 2.0 normalized cell viability normalized cell viability 1.5 Significantt Significantt siRNA deconvolution Growth in in LNCaP-16D tandard med 5-7 day later 1.0 Not Significant 1465861482153 Not Significantt LNCaP-abl 3568709268134 0.5 24647485801387 LNCaP-Enza<sup>R</sup> 82145000153734 LNCaP-16D CellTiter-Blue (viability) Analysis and 0.0 measurements hit identification FOXA1 GATA2 NKX3-1 CREB1 TLE3 HORIZ HORIZ<br>ARIZ DAN<br>ARIZ HORIZ HO<br>ARIZ HORIZ HO FOXA1 GATA2 NKX3-1 CREB1 HDAC3 TLE3 PIAS1 ASH2L HOXB13 NR 1<br>LOP<br>HORS<br>SUMO2<br>SUMO2 FOXA1 GATA2 NKX3-1 CREB1 HDAC3 TLE3 PIAS1 ASH2L HOXB13 NR3C1 TOP<br>HDAC3<br>HDAC3<br>HOC2<br>HOC2 HDAC3 **HOTBITS** F GATA2 E  $x_0$ Askil<sup>2</sup> **NATISTS NR3C1** CREB1 PIAS1 LNCaP **HDAC3** TOP<sup>1</sup> HSA synergy score: 13.318  $\mathscr{\mathscr{L}}$  $-30 -20 -100 -100 -100 -200 -30$ 1.25 10000.0 1.00 3881.5 normalized cell viability normalized cell viability ENZA (nM) ENZA (nM) Significant Significantt 1506.6 0.75 ۴ 584.8 m. 0.50 F 227.0 0.25



Not Significantt Not Significantt 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 PDX explant 23.1 HSA synergy score: 20.91 −40 −20 0 20 40





G

0.00



**vorinostat**

**enzalutamide**

0.<sup>0</sup> 64.9 11.0 210.1 319.6 684.0 1232.3 Vorinostat (nM)

 $-40$   $-20$  0 20 40 HSA synergy score: 12.806

Vorinostat (nM)

LNCaP-16D

ENZA (nM)

ENZA (nM)

 $0.0$ 

0.0

88.1

227.0

584.8

1506.6

3881.5

10000.0

 $\sigma_{\cal O}$ 64.9 110 210.7 379.6 **684.0** 1232.3

88.1